These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 13725854)

  • 1. Effect of hypotensive therapy on renal functional pattern in cases of hypertension.
    EFFAT S; MAHDI MA; ELEBRASHY N
    J Egypt Med Assoc; 1960; Suppl 43():507-20. PubMed ID: 13725854
    [No Abstract]   [Full Text] [Related]  

  • 2. [The effect of guanethidine on hypertension and renal function in the therapy of hospitalized and ambulant patients].
    COTTIER P; REUBI F; DUPASQUIER E
    Dtsch Med Wochenschr; 1960 Jul; 85():1263-71. PubMed ID: 13695886
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comparative study on the effect of various hypotensive agents on the blood pressure and kidney function after prolonged therapy].
    COTTIER P; ZIMMERLI A
    Helv Med Acta; 1959 Nov; 26():648-54. PubMed ID: 13812314
    [No Abstract]   [Full Text] [Related]  

  • 4. [The effect of prolonged guanethidine administration on the kidney function of hypertensive patients].
    BARTORELLI C; GARGANO N; REGOLI D; ZANCHETTI A
    Dtsch Med Wochenschr; 1960 Jul; 85():1271-5. PubMed ID: 13687501
    [No Abstract]   [Full Text] [Related]  

  • 5. Role of the renal nerves in gamma-aminobutyric acid-induced antihypertensive effect in spontaneously hypertensive rats.
    Hayakawa K; Kimura M; Yamori Y
    Eur J Pharmacol; 2005 Nov; 524(1-3):120-5. PubMed ID: 16256107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can calcium channel blockers preserve renal function better than diuretics during antihypertensive treatment?
    Fukuda M; Kimura G
    Arch Intern Med; 2005 Jun; 165(11):1312; author reply 1312-3. PubMed ID: 15956015
    [No Abstract]   [Full Text] [Related]  

  • 8. Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.
    Steinman TI
    Nephrol Dial Transplant; 2008 Feb; 23(2):431-3. PubMed ID: 18065782
    [No Abstract]   [Full Text] [Related]  

  • 9. A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension.
    Wang H; Long CL; Zhang YL
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1326-33. PubMed ID: 15525792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of blood pressure control in chronic kidney disease.
    Ravera M; Re M; Deferrari L; Vettoretti S; Deferrari G
    J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S98-103. PubMed ID: 16565257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihypertensive effect of a standardized aqueous extract of Cecropia glaziovii Sneth in rats: an in vivo approach to the hypotensive mechanism.
    Lima-Landman MT; Borges AC; Cysneiros RM; De Lima TC; Souccar C; Lapa AJ
    Phytomedicine; 2007 May; 14(5):314-20. PubMed ID: 17446057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Are all antihypertensive drugs renoprotective?].
    Wolf S; Risler T
    Herz; 2004 May; 29(3):248-54. PubMed ID: 15167950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.
    Zeltner R; Poliak R; Stiasny B; Schmieder RE; Schulze BD
    Nephrol Dial Transplant; 2008 Feb; 23(2):573-9. PubMed ID: 17984104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypotensive effect of oxatriazolium-5-olate derivative].
    Artem'eva MM; Postnikov AB; Akinfrieva OV; Daliger IL; Shevelev SA; Medvedev OS; Medvedeva NA
    Eksp Klin Farmakol; 2008; 71(5):25-7. PubMed ID: 19093367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.
    Ferrari P; Ferrandi M; Valentini G; Manunta P; Bianchi G
    Med Hypotheses; 2007; 68(6):1307-14. PubMed ID: 17097240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcium channel blockers and nephroprotection.
    Ungar A; Di Serio C; Lambertucci L; Monami M; Masotti G
    Aging Clin Exp Res; 2005 Aug; 17(4 Suppl):31-9. PubMed ID: 16640171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparative evaluation of hypotensive drugs in experimental renal hypertension].
    MARDAKHIASHVILI ShI
    Farmakol Toksikol; 1961; 24():161-3. PubMed ID: 13766609
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechanisms involved in the hypotensive effect of a kappa-opioid receptor agonist in hypertensive rats.
    Guo HT; Zhang RH; Huang LY; Li J; Liu YL; Bi H; Zhang QY; Wang YM; Sun X; Ma XL; Cheng L; Liu JC; Yu SQ; Yi DH; Pei JM
    Arch Med Res; 2007 Oct; 38(7):723-9. PubMed ID: 17845890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure versus direct mineralocorticoid effects on kidney inflammation and fibrosis in DOCA-salt hypertension.
    Klanke B; Cordasic N; Hartner A; Schmieder RE; Veelken R; Hilgers KF
    Nephrol Dial Transplant; 2008 Nov; 23(11):3456-63. PubMed ID: 18515791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complex role of PPARgamma in renal dysfunction in obesity: managing a Janus-faced receptor.
    Dobrian AD
    Vascul Pharmacol; 2006 Jul; 45(1):36-45. PubMed ID: 16716756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.